A Phase 4 interventional study of mesalamine in Ulcerative Colitis, sponsored by James Lewis. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-05.
Sponsored by James Lewis · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing mesalamine in Colitis, Ulcerative — 5 open to participants now, 6 under way, 1 of them phase 3. Mesalamine · Colitis, Ulcerative.
Among the 50 studies testing mesalamine in Colitis, Ulcerative, this one is the 30th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2008, is one of 13 in phase 4, and was the 19th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 50 studies testing mesalamine in Colitis, Ulcerative are open now, in 3 countries. Recruiting first, the newest first:
The Second Hospital of Nanjing Medical University · Sites in China
Ages 18–75
Flemming Bendtsen · Sites in Denmark
Ages 18–60
University Hospital, Linkoeping · Sites in Sweden
Ages 18–70
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18+
Faes Farma, S.A.
Ages 18+
By country, each count listing its studies:
Mesalamine: first FDA approval 1987 (ROWASA). What it is approved for, and how studies give it, is on its page →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 2 · Phase 3 26 · Phase 4 13
First in 2000; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 70 across 1,239 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 206 across the 49 interventional studies. Of the 42 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 50 have an industry lead sponsor. The 10 most frequent:
James Lewis is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
James Lewis has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing mesalamine in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels \<50µg/g stool will be observed for 48 weeks. All patients will have FCP concentration measured using a commercially available assay at enrollment, 6 weeks and 12 weeks. All patients with persistently elevated FCP will receive one or both of the following interventions: change in the mesalamine formulation to Lialda and/or increase in the dose of Lialda. Reduction in FCP levels below 50µg/g stool 6 weeks after randomization will be the primary outcome. The proportion of patients achieving this outcome will be compared between groups using Fisher's exact test. All randomized patients as well as those who were excluded from the randomized trial because of a low FCP concentration at baseline will be followed to week 48 to determine the rate of clinical relapse.
Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse. We performed an open-label, randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin (FC) in patients with quiescent UC.
We screened 119 patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores, FC >50 µg/g, and intake of no more than 3 g/day mesalamine. Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine (2.4 g/day) for 6 weeks; 52 participants were then randomly assigned (1:1) to a group that continued its current dose of mesalamine (controls, n = 26) or a group that increased its dose by 2.4 g/day for 6 weeks (n = 26). The primary outcome was continued remission with FC \<50 µg/g. Secondary outcomes were continued remission with FC \<100 µg/g or \<200 µg/g (among patients with pre-randomization values above these levels).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Increase dose of mesalamine by 2.4 gm per day
Drug: mesalamine
Maintain current mesalamine dose at 2.4 g/day
Increase dose by 2.4gm per day over baseline dose
Also known as: Lialda
Fecal Calprotectin Level <50µg/g
Time frame: 6 weeks after randomization
Fecal Calprotectin Level <100 µg/g
Time frame: at 6 weeks after randomization
Fecal Calprotectin <200 µg/g
Time frame: at 6 weeks after randomization
We screened 150 patients and enrolled 119 patients with UC in remission on the basis of SCCAI score. 58 patients had baseline fecal calprotectin(FC) \<50 µg/g. These patients were followed in an observational arm. 61 had FC \>= 50 µg/g,whose current mesalamine dose \<3g/day. See preassignment details.
| Milestone | Increase Dose of Mesalamine | Maintain Baseline Mesalamine Dose |
|---|---|---|
| Started | 26 | 26 |
| Completed | 26 | 26 |
| Not completed | 0 | 0 |
| participants | Increase Mesalamine Dose by 2.4g/Day | Maintain Mesalmine Dose |
|---|---|---|
| Fecal Calprotectin Level <50µg/g | 7 | 1 |
| participants | Increase Dose of Mesalamine | Maintain Baseline Mesalamine Dose |
|---|---|---|
| Fecal Calprotectin Level <100 µg/g | 10 | 3 |
| participants | Increase Dose of Mesalamine | Maintain Baseline Mesalamine Dose |
|---|---|---|
| Fecal Calprotectin <200 µg/g | 10 | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Increase Dose of Mesalamine | — | 0/26 (0%) | 11/26 (42.3%) |
| Maintain Baseline Mesalamine Dose | — | 0/26 (0%) | 7/26 (26.9%) |
| Event | Increase Dose of Mesalamine | Maintain Baseline Mesalamine Dose |
|---|---|---|
| diarrheaGastrointestinal disorders | 3/26 | 1/26 |
| blood in stoolGastrointestinal disorders | 1/26 | 2/26 |
| BloatingGastrointestinal disorders | 2/26 | 0/26 |
| Abdominal painGastrointestinal disorders | 0/26 | 1/26 |
| acneSkin and subcutaneous tissue disorders | 0/26 | 1/26 |
| ConstipationGastrointestinal disorders | 0/26 | 1/26 |
| dizzinessGeneral disorders | 1/26 | 0/26 |
| FatigueGeneral disorders | 1/26 | 0/26 |
| FeverInfections and infestations | 1/26 | 0/26 |
| FlatulenceGastrointestinal disorders | 1/26 | 1/26 |
| Age, Continuous(years) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Median | 43.8 (30.5 to 57.1) | 48.8 (33.5 to 60.4) | 46.5 (32.0 to 58.0) |
| Sex: Female, Male(Participants) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Female | 11 | 13 | 24 |
| Male | 15 | 13 | 28 |
| Race (NIH/OMB)(Participants) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 22 | 21 | 43 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| United States | 26 | 26 | 52 |
| Tobacco use(participants) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Current | 0 | 2 | 2 |
| Prior | 6 | 8 | 14 |
| Never | 20 | 16 | 36 |
| Extent of disease(participants) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Proctitis | 8 | 2 | 10 |
| Left-sided | 9 | 12 | 21 |
| Extensive | 9 | 11 | 20 |
| Other | 0 | 1 | 1 |
| Median duration of UC(years) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Median | 11.9 (3.7 to 19.8) | 6.5 (2.2 to 11.9) | 8.9 (2.8 to 15.9) |
| Median of duration of remission at baseline(years) | Increase Mesalamine Dose | Maintain Mesalamine Dose | Total |
|---|---|---|---|
| Median | 0.3 (0.2 to 1.0) | 0.5 (0.2 to 1.1) | 0.4 (0.2 to 1.0) |
8 further baseline measures are reported on the registry.
The record gives a start of Sep 2008, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2015, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mesalamine
James Lewis